Cover Image
市場調查報告書

亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場預測

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

出版商 GBI Research 商品編碼 358649
出版日期 內容資訊 英文 161 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場預測 Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
出版日期: 2017年03月09日 內容資訊: 英文 161 Pages
簡介

亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場,預計從2016年的30億美元,擴大到2023年的62億美元,2016年∼2023年以10.8%的年複合成長率成長。

本報告提供亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場相關調查分析,上市產品,開發平台,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 上市產品

  • 概要
  • 化療
    • Alimta (pemetrexed) - Eli Lilly
    • Abraxane (paclitaxel) - Celgene
  • 表皮生長因子受體蛋白酪氨酸激梅抑制劑
    • Tarceva (erlotinib) - Roche
    • Iressa (gefitinib) - AstraZeneca
    • Gilotrif/Giotrif/Xovoltib (afatinib) - Boehringer Ingelheim
    • Tagrisso (osimertinib/AZD-9291) - AstraZeneca
    • Olita (olmutinib) - Hanmi Pharmaceuticals
    • Conmana (icotinib) - Betta Pharmaceuticals
  • 未分化淋巴瘤激梅蛋白酪氨酸激梅抑制劑
    • Xalkori (crizotinib) - Pfizer
    • Alecensa (alectinib) - Roche
    • Zykadia (ceritinib/LDK378) - Novartis
  • 程式性細胞死亡蛋白質1/計劃死免疫查核點抑制劑
    • Opdivo (nivolumab) - Bristol-Myers Squibb
    • Keytruda (pembrolizumab) - Merck & Co
  • 其他
    • Avastin (bevacizumab) - Roche
    • Cyramza (Ramucirumab) - Eli Lilly
    • Ofev/Vargatef (Nintedanib) - Boehringer Ingelheim
  • 結論
  • 上市產品的有效性和安全性比較

第4章 開發平台分析

  • 概要
  • 開發平台:各開發階段,分子類型,給藥途徑,計劃類型
  • 開發平台:各分子標的
  • 有前途的開發平台候補藥
  • 開發中產品的有效性和安全性比較
  • 產品競爭力架構

第5章 臨床實驗分析

  • 失敗率
  • 臨床實驗的規模
  • 臨床實驗的期間
  • 臨床實驗標準的摘要

第6章 複數方案的預測

  • 概要
  • 亞太地區市場
  • 印度
  • 中國
  • 澳洲
  • 韓國
  • 日本

第7章 市場動態 (推動因素與阻礙)

  • 推動因素
  • 障礙

第8章 交易與策略性整合

  • 共同開發交易
  • 授權交易

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GBIHC437MR

Executive Summary

Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 60 and over - a high-risk age range for lung cancer. Over half of the incident cases of non-small cell lung cancer (NSCLC) are diagnosed in patients over the age of 65. The percentage of people above 65 in 2016 and 2014 was 27.2% and 25.8% in Japan; 10.3% and 9.6% in China; 6% and 5.8% in India; 15.8% and 15% in Australia; and 13.5% and 13% in South Korea. The increase in the ageing population will drive NSCLC prevalence. Smoking is the main cause of lung cancer, ahead of radon gas, inhalation of chemical carcinogens and genetic factors. Although the number of smokers is falling in Asia-Pacific (APAC), the prevalence of NSCLC is increasing.

The NSCLC market in Asia-Pacific is forecast to grow substantially, from $3 billion in 2016 to $6.2 billion in 2023, at a compound annual growth rate (CAGR) of 10.8%. As per Gayathri Kanika, GBI Research, "Owing to strong clinical performances, immune-checkpoint inhibitors will have a greater uptake than other second-line market entrants and will compete among themselves for market share in the APAC region." The entry of targeted therapies into the market will offset the effect of patent expiries for drugs such as Avastin, Alimta, and Tarceva, which will have a limited impact on the market between 2016 and 2023.

New targeted and immuno-therapies will drive market growth due to premium pricing and strong clinical performances, but they will also increase the degree of NSCLC market segmentation and the complexity of the treatment algorithm, owing to their enhanced efficacy in specific patient populations. The limited effect of patent expiry on the NSCLC market is one of the main reasons for the substantial growth in value expected in the forecast period, as the introduction of numerous therapies will not be offset by generic erosion; instead, premium therapies will occupy a larger market share for much of the forecast period in APAC.

The rate of mutation testing is very low in China and India compared with Australia, South Korea and Japan, and this makes many patients ineligible to receive targeted therapies. However, it is increasing, driven by increasing awareness among the healthcare fraternity. Hence, targeted therapies are expected to be used more often, driving market growth. Moreover, healthcare access and awareness have improved in India and China due to government initiatives. This will increase the market size by strengthening the treatment pool.

The report "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" provides the following -

  • Detailed analysis of the products currently marketed for NSCLC, detailing their key characteristics, including safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, pricing, and overall competitive strength.
  • Provides detailed analysis of the pipeline for NSCLC by stage of development, molecule type, program type, mechanism of action and molecular target and also analyzes recent clinical trials in this indication by enrollment, duration and failure rate, and provides a primary endpoint analysis of NSCLC clinical trials.
  • Market forecasts for the NSCLC market, covering epidemiology, treatment usage patterns, pricing and market size for the 2016-2023 forecast period. Five APAC markets -India, China, Australia, South Korea and Japan- are covered, and data are presented at a country-by-country level, with further analysis of key market drivers and barriers.
  • It describes the major deals that have taken place in the APAC NSCLC market in recent years.

Scope

The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.

  • How will immunotherapies such as atezolizumab contribute to growth?
  • What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
  • What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
  • How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Adenocarcinoma
    • 2.4.2. Squamous-Cell Carcinoma
    • 2.4.3. Large-Cell Carcinoma
    • 2.4.4. Immunotherapy
  • 2.5. Diagnosis
  • 2.6. Prognosis
  • 2.7. Treatment Guidelines and Options
    • 2.7.1. Treatment Algorithm
    • 2.7.2. First-Line Treatment
    • 2.7.3. Maintenance Therapy
    • 2.7.4. Second-Line Treatment
    • 2.7.5. Third-Line Therapy
    • 2.7.6. Adjuvant Therapy

3. Marketed Products

  • 3.1. Overview
  • 3.2. Chemotherapies
    • 3.2.1. Alimta (pemetrexed) - Eli Lilly
    • 3.2.2. Abraxane (paclitaxel) - Celgene
  • 3.3. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    • 3.3.1. Tarceva (erlotinib) - Roche
    • 3.3.2. Iressa (gefitinib) - AstraZeneca
    • 3.3.3. Gilotrif/Giotrif/Xovoltib (afatinib) - Boehringer Ingelheim
    • 3.3.4. Tagrisso (osimertinib/AZD-9291) - AstraZeneca
    • 3.3.5. Olita (olmutinib) - Hanmi Pharmaceuticals
    • 3.3.6. Conmana (icotinib) - Betta Pharmaceuticals
  • 3.4. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors
    • 3.4.1. Xalkori (crizotinib) - Pfizer
    • 3.4.2. Alecensa (alectinib) - Roche
    • 3.4.3. Zykadia (ceritinib/LDK378) - Novartis
  • 3.5. Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
    • 3.5.1. Opdivo (nivolumab) - Bristol-Myers Squibb
    • 3.5.2. Keytruda (pembrolizumab) - Merck & Co
  • 3.6. Other
    • 3.6.1. Avastin (bevacizumab) - Roche
    • 3.6.2. Cyramza (Ramucirumab) - Eli Lilly
    • 3.6.3. Ofev/Vargatef (Nintedanib) - Boehringer Ingelheim
  • 3.7. Conclusion
  • 3.8. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Analysis

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.3. Pipeline by Molecular Target
  • 4.4. Promising Pipeline Candidates
    • 4.4.1. Yervoy (Ipilimumab) - Bristol-Myers Squibb
    • 4.4.2. Tecentriq (Atezolizumab) - Roche
    • 4.4.3. Necitumumab - Eli Lilly
    • 4.4.4. Durvalumab plus Tremelimumab (MEDI-4736/MEDI-1123) - MedImmune
    • 4.4.5. Veliparib - AbbVie
    • 4.4.6. Vaxira - Recombio
    • 4.4.7. Abemaciclib - Eli Lilly
    • 4.4.8. Dacomitinib - Pfizer
    • 4.4.9. Ensartinib (X-396) - Xcovery
    • 4.4.10. Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing
    • 4.4.11. CimaVax-EGF (BVNSCLC-001) - Bioven
    • 4.4.12. Brigatinib (AP-26113) - Ariad Pharmaceuticals
    • 4.4.13. Naquotinib Mesylate (ASP8273) - Astellas Pharma
    • 4.4.14. Plinabulin - BeyondSpring Pharma
    • 4.4.15. Fruquintinib (HMPL-013) - Hutchison MediPharma
    • 4.4.16. Famitinib (SHR-1020) - Jiangsu Hengrui Medicine
    • 4.4.17. Vandetanib (ZD 6474) - Genzyme
    • 4.4.18. Aitan (Apatinib) - Jiangsu Hengrui Medicine
  • 4.5. Comparative Efficacy and Safety of Pipeline Products
  • 4.6. Product Competitiveness Framework

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Size
    • 5.2.1. Patient Enrollment per Product by Molecule Type and Stage of Development
    • 5.2.2. Patient Enrollment per Product by Molecular Target and Stage of Development
    • 5.2.3. Patient Enrollment per Trial by Molecule Type and Stage of Development
    • 5.2.4. Patient Enrollment per Trial by Molecular Target and Stage of Development
  • 5.3. Clinical Trial Duration
    • 5.3.1. Trial Duration by Molecule Type and Stage of Development
    • 5.3.2. Trial Duration by Molecular Target and Stage of Development
  • 5.4. Summary of Clinical Trial Metrics

6. Multi-scenario Forecast

  • 6.1. Overview
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. South Korea
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size
  • 6.7. Japan
    • 6.7.1. Treatment Usage Patterns
    • 6.7.2. Annual Cost of Therapy
    • 6.7.3. Market Size

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. Increasing Pollution and Passive Smoking to Drive the Incidence
    • 7.1.2. Increasing Elderly Population and Incidence of NSCLC
    • 7.1.3. The Availability of Novel First- and Second-Line Therapy Options in Pipeline
    • 7.1.4. Increase in Mutation Testing to Drive Market Growth
    • 7.1.5. Diversified Healthcare Reform to Boost Market Growth
    • 7.1.6. Diversified Health Insurance System to Help Nurture Growth
  • 7.2. Barriers
    • 7.2.1. Patent Expiration of Branded Therapies to Affect NSCLC Market Growth
    • 7.2.2. High Prices of Therapeutics to Slow Down Market Growth
    • 7.2.3. Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India
    • 7.2.4. Drug Pricing Reforms

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.1.4. Key Licensing Deals
  • 8.2. Co-development Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.2.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.2.4. Key Co-development Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Stage of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Investigational New Drug/Clinical Trial Authorization-Filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Summary of Multi-scenario Market Forecasts to 2023
    • 9.2.1. Asia-Pacific
    • 9.2.2. India
    • 9.2.3. China
    • 9.2.4. Australia
    • 9.2.5. South Korea
    • 9.2.6. Japan
  • 9.3. Bibliography
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: NSCLC Therapeutics Market, Tumor Node Metastasis Classification
  • Table 2: NSCLC Therapeutics Market, Eastern Co-operative Oncology Group Criteria
  • Table 3: NSCLC Therapeutics Market, Treatment Options
  • Table 4: NSCLC Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2006-2016
  • Table 5: NSCLC Therapeutics Market, Global, Co-development Deals Value, 2006-2016
  • Table 6: NSCLC Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
  • Table 7: NSCLC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017
  • Table 8: Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2017
  • Table 9: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
  • Table 10: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
  • Table 11: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
  • Table 12: NSCLC Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017
  • Table 13: NSCLC Therapeutics Market, APAC, Market Forecast, 2016-2023
  • Table 14: NSCLC Therapeutics Market, India, Market Forecast, 2016-2023
  • Table 15: NSCLC Therapeutics Market, China, Market Forecast, 2016-2023
  • Table 16: NSCLC Therapeutics Market, Australia, Market Forecast, 2016-2023
  • Table 17: NSCLC Therapeutics Market, South Korea, Market Forecast, 2016-2023
  • Table 18: NSCLC Therapeutics Market, Japan, Market Forecast, 2016-2023

List of Figures

  • Figure 1: NSCLC Therapeutics Market, Australia, Age-Specific Incidence Rate (per 100,000), 2000-2012
  • Figure 2: NSCLC Therapeutics Market, Global, Molecular Characteristic Frequency (%)
  • Figure 3: NSCLC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for First-line Treatment
  • Figure 4: NSCLC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Maintenance Therapy
  • Figure 5: NSCLC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Treatment of Second-line Treatment
  • Figure 6: NSCLC Therapeutics Market, Global, Pipeline, 2017
  • Figure 7: NSCLC Therapeutics Market, Global, Pipeline by Molecular Target, 2017
  • Figure 8: NSCLC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017
  • Figure 9: NSCLC Therapeutics Market, APAC, Ipilimumab Forecast ($m), 2019-2023
  • Figure 10: NSCLC Therapeutics Market, APAC, Atezolizumab Forecast ($m), 2020-2023
  • Figure 11: NSCLC Therapeutics Market, APAC, Necitumumab Forecast ($m), 2019-2023
  • Figure 12: NSCLC Therapeutics Market, APAC, Durvalumab plus Tremelimumab Forecast ($m), 2020-2023
  • Figure 13: NSCLC Therapeutics Market, APAC, Veliparib Forecast ($m), 2019-2023
  • Figure 14: NSCLC Therapeutics Market, APAC, Vaxira Forecast ($m), 2019-2023
  • Figure 15: NSCLC Therapeutics Market, APAC, Abemaciclib Forecast ($m), 2020-2023
  • Figure 16: NSCLC Therapeutics Market, APAC, Dacomitinib Forecast ($m), 2019-2023
  • Figure 17: NSCLC Therapeutics Market, APAC, Ensartinib Forecast ($m), 2022-2023
  • Figure 18: NSCLC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for First-line Treatment
  • Figure 19: NSCLC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for Second-line Treatment
  • Figure 20: NSCLC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for Third-line Treatment
  • Figure 21: NSCLC Therapeutics Market, Competitor Matrix for NSCLC Marketed and Pipeline First-Line Products, 2017
  • Figure 22: NSCLC Therapeutics Market, Competitor Matrix for NSCLC Marketed and Pipeline Second-Line Products, 2017
  • Figure 23: NSCLC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
  • Figure 24: NSCLC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
  • Figure 25: NSCLC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
  • Figure 26: NSCLC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016
  • Figure 27: NSCLC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016
  • Figure 28: NSCLC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016
  • Figure 29: NSCLC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016
  • Figure 30: NSCLC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016
  • Figure 31: NSCLC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016
  • Figure 32: NSCLC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 33: NSCLC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 34: NSCLC Therapeutics Market, APAC, Treatment Patterns ('000), 2016-2023
  • Figure 35: NSCLC Therapeutics Market, APAC, Market Size ($bn), 2016-2023
  • Figure 36: NSCLC Therapeutics Market, India, Treatment Patterns ('000), 2016-2023
  • Figure 37: NSCLC Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
  • Figure 38: NSCLC Therapeutics Market, India, Market Size ($m), 2016-2023
  • Figure 39: NSCLC Therapeutics Market, China, Treatment Patterns ('000), 2016-2023
  • Figure 40: NSCLC Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
  • Figure 41: NSCLC Therapeutics Market, China, Market Size ($bn), 2016-2023
  • Figure 42: NSCLC Therapeutics Market, Australia, Treatment Patterns ('000), 2016-2023
  • Figure 43: NSCLC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
  • Figure 44: NSCLC Therapeutics Market, Australia, Market Size ($m), 2016-2023
  • Figure 45: NSCLC Therapeutics Market, South Korea, Treatment Patterns ('000), 2016-2023
  • Figure 46: NSCLC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
  • Figure 47: NSCLC Therapeutics Market, South Korea, Market Size ($m), 2016-2023
  • Figure 48: NSCLC Therapeutics Market, Japan, Treatment Patterns ('000), 2016-2023
  • Figure 49: NSCLC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
  • Figure 50: NSCLC Therapeutics Market, Japan, Market Size ($bn), 2016-2023
  • Figure 51: NSCLC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
  • Figure 52: NSCLC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
  • Figure 53: NSCLC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
  • Figure 54: NSCLC Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
  • Figure 55: NSCLC Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
  • Figure 56: NSCLC Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016
  • Figure 57: NSCLC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
  • Figure 58: NSCLC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
  • Figure 59: NSCLC Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2016
  • Figure 60: NSCLC Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016
Back to Top